Zobrazeno 1 - 10
of 21
pro vyhledávání: '"J C, Tercero"'
Autor:
Bradley J. Monk, Stanley B. Kaye, Claudia Lebedinsky, Songbai Wang, P. Zintl, Trilok V. Parekh, Andres Poveda, Deborah Ricci, J. C. Tercero, Robert McCormack
Publikováno v:
Gynecologic Oncology. 122:567-572
Serial circulating tumor cell (CTC) counts have demonstrated predictive and prognostic value in patients with metastatic breast, colorectal, and prostate cancer. In a phase III study of pegylated liposomal doxorubicin (PLD) with trabectedin vs. PLD f
Autor:
Palma Dileo, Paola Collini, Roberta Sanfilippo, S. Pilotti, J. Jimeno, J. C. Tercero, Carlo Morosi, Emanuela Virdis, Paolo G. Casali, C. Piovesan, Maurizio D'Incalci, Alessandro Gronchi, Federica Grosso
Publikováno v:
Annals of Oncology. 20:1439-1444
Background Trabectedin has been approved in Europe as second-line therapy for advanced soft tissue sarcomas. A previous analysis showed that myxoid liposarcomas (MLS) are particularly sensitive to the drug. We report on the long-term efficacy of trab
Autor:
Sarah Uboldi, S Di Giandomenico, Monica Ganzinelli, Giovanna Damia, Anna Pastore, Maurizio D'Incalci, Geoffrey P. Margison, Luca Clivio, Anna Maria Caccuri, Andrea Fossati, Eugenio Erba, Elena Marangon, O Capozzi, M. Romano, Federica Grosso, Sergio Bernasconi, Amanda J. Watson, M Rocchi, I Fuso Nerini, Federica Sala, Roberto Mantovani, Sergio Marchini, Giovanna Chiorino, J. C. Tercero
Myxoid Liposarcomas (MLS), characterized by the expression of FUS-CHOP fusion gene are clinically very sensitive to the DNA binding antitumor agent, trabectedin. However, resistance eventually occurs, preventing disease eradication. To investigate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a83c1380bfac3594fb417e4b96a40a9
http://hdl.handle.net/2108/64209
http://hdl.handle.net/2108/64209
Autor:
Jean-Yves Blay, Binh Bui, George D. Demetri, S. Pilotti, Antonio Nieto, Elena Tamborini, S. Bonvalot, Pilar Lardelli, Vicente Alfaro, J. C. Tercero, A. Le Cesne, Peter Hohenberger, Raymond J. Hohl, Alessandro Gronchi, I. Perez, Silvia Ferrari
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 23(3)
Background To evaluate neoadjuvant trabectedin (1.5 mg/m2 24-h i.v. infusion every 3 weeks; three to six cycles) in patients with locally advanced myoxid liposarcoma (ML) previously untreated with chemotherapy or radiation. Patients and methods Prima
Autor:
Robert G. Maki, Andres Poveda, J. C. Tercero, Federica Grosso, Paolo G. Casali, Rafael Rosell, Miquel Taron, A. Le Cesne, Robin L. Jones, Patrick Schöffski, Antonio Nieto, R. Sanfilipio, J.-Y. Blay, J. Jimeno
Publikováno v:
European journal of cancer (Oxford, England : 1990). 47(7)
Aim Trabectedin sensitivity is increased in cells with functional nucleotide excision DNA repair, whereas efficient homologous recombination repair leads to resistance. On this basis, a retrospective study of mRNA expression of BRCA1 (breast cancer s
Autor:
J C Tercero, Reed B. Wickner
Publikováno v:
Journal of Biological Chemistry. 267:20277-20281
The MAK3 gene is necessary for propagation of the L-A double-stranded RNA virus of Saccharomyces cerevisiae. MAK3 encodes a protein with substantial homology to the Escherichia coli rimI N-acetyltransferase that acetylates the NH2 terminus of ribosom
Publikováno v:
Journal of Biological Chemistry. 267:20270-20276
The MAK3 gene of Saccharomyces cerevisiae is necessary for the propagation of the L-A double-stranded RNA virus and its satellites, such as M1 that encodes a killer toxin. We cloned the MAK3 gene based on its genetic map position using physically map
Publikováno v:
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 4(8)
Cases of rifampin-resistant Mycobacterium tuberculosis from the prison population in Madrid and from the general population in Spain.To identify the rpoB mutations associated with resistance to rifampin and to investigate rpoB genotyping as an epidem
Autor:
J. Alemany, Guillermo Suárez, Ernesto Liebana, M Vilafranca, Alicia Aranaz, Mariano Domingo, E Gomez-Mampaso, Ana Mateos, Lucas Domínguez, J C Tercero
Publikováno v:
Universitat Autònoma de Barcelona
Europe PubMed Central
Scopus-Elsevier
Europe PubMed Central
Scopus-Elsevier
Mycobacterium bovis is a slowly growing microorganism, and confirmation of the diagnosis by conventional culture is a lengthy process. A simple, rapid method for the extraction of DNA from bovine tissue samples was developed and used in a PCR designe
Autor:
Jan Lubinski, Joanne L. Blum, J. C. Tercero, K. L. Tedesco, Frankie A. Holmes, A. Goncalves, Pilar Lardelli, Suzette Delaloge, Cynthia Osborne, A. Florez
Publikováno v:
Journal of Clinical Oncology. 29:1125-1125
1125 Background: Single-agent T has shown antitumor activity in pts with pretreated MBC. Preclinical data suggested T displays increased activity in cell lines having intact nucleotide excision repair (NER), evidenced in particular by XPG expression